Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding

Affiliations

¹ Department of Infectious Diseases, Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia; St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia. Electronic address: gdore@kirby.unsw.edu.au.
² Department of Gastroenterology, St Vincent's Clinical School, Darlinghurst, NSW, Australia; St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
³ Department of Infectious Diseases, Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia; St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.

Comment

Gregory J Dore et al. Lancet Gastroenterol Hepatol. 2020 Dec.

. 2020 Dec;5(12):1028-1029.

doi: 10.1016/S2468-1253(20)30270-3. Epub 2020 Sep 30.

¹ Department of Infectious Diseases, Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia; St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia. Electronic address: gdore@kirby.unsw.edu.au.
² Department of Gastroenterology, St Vincent's Clinical School, Darlinghurst, NSW, Australia; St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
³ Department of Infectious Diseases, Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia; St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.

No abstract available

Comment on

Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Tseng CH, et al. Lancet Gastroenterol Hepatol. 2020 Dec;5(12):1039-1052. doi: 10.1016/S2468-1253(20)30249-1. Epub 2020 Sep 30. Lancet Gastroenterol Hepatol. 2020. PMID: 33007228